华特达因子公司取得一项药品注册证书

Core Viewpoint - The company announced that its subsidiary, Shandong Dain Pharmaceutical Co., Ltd., has received a drug registration certificate from the National Medical Products Administration for a new medication, Clonidine Hydrochloride Sustained-Release Tablets, aimed at treating Attention Deficit Hyperactivity Disorder (ADHD) in children and adolescents aged 6-17 years [1] Group 1 - The drug is indicated for use either alone or as an adjunct to central nervous system stimulants in the treatment of ADHD [1]